6 octobre 2022 Offre M1 ou M2 B2PM – Development of a gene therapy treatment for a rare lysosomal disorder Read More
6 octobre 2022 Offre M1 ou M2 B2PM – Universal gene editing strategies to treat Duchenne Muscular Dystrophy. Read More
6 octobre 2022 Offre M2 B2PM – Study of CRISPR/Cas9-induced genomic alterations as a result of targeted therapeutic genome editing. Read More
